Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells

Keiki Sugimoto, Fumihiko Hayakawa, Satoko Shimada, Takanobu Morishita, Kazuyuki Shimada, Tomoya Katakai, Akihiro Tomita, Hitoshi Kiyoi, Tomoki Naoe

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Cell lines have been used for drug discovery as useful models of cancers; however, they do not recapitulate cancers faithfully, especially in the points of rapid growth rate and microenvironment independency. Consequently, the majority of conventional anti-cancer drugs are less sensitive to slow growing cells and do not target microenvironmental support, although most primary cancer cells grow slower than cell lines and depend on microenvironmental support. Here, we developed a novel high throughput drug screening system using patient-derived xenograft (PDX) cells of lymphoma that maintained primary cancer cell phenotype more than cell lines. The library containing 2613 known pharmacologically active substance and off-patent drugs were screened by this system. We could find many compounds showing higher cytotoxicity than conventional anti-tumor drugs. Especially, pyruvinium pamoate showed the highest activity and its strong anti-tumor effect was confirmed also in vivo. We extensively investigated its mechanism of action and found that it inhibited glutathione supply from stromal cells to lymphoma cells, implying the importance of the stromal protection from oxidative stress for lymphoma cell survival and a new therapeutic strategy for lymphoma. Our system introduces a primary cancer cell phenotype into cell-based phenotype screening and sheds new light on anti-cancer drug development.

Original languageEnglish
Article number13054
JournalScientific Reports
Volume5
DOIs
Publication statusPublished - 17-08-2015
Externally publishedYes

Fingerprint

Drug Delivery Systems
Heterografts
Lymphoma
Neoplasms
Phenotype
Cell Line
Pharmaceutical Preparations
Preclinical Drug Evaluations
Drug Discovery
Stromal Cells
Libraries
Glutathione
Cell Survival
Oxidative Stress
Growth

All Science Journal Classification (ASJC) codes

  • General

Cite this

Sugimoto, K., Hayakawa, F., Shimada, S., Morishita, T., Shimada, K., Katakai, T., ... Naoe, T. (2015). Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. Scientific Reports, 5, [13054]. https://doi.org/10.1038/srep13054
Sugimoto, Keiki ; Hayakawa, Fumihiko ; Shimada, Satoko ; Morishita, Takanobu ; Shimada, Kazuyuki ; Katakai, Tomoya ; Tomita, Akihiro ; Kiyoi, Hitoshi ; Naoe, Tomoki. / Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. In: Scientific Reports. 2015 ; Vol. 5.
@article{1fbb69637ae44492b8ace02a810d84c5,
title = "Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells",
abstract = "Cell lines have been used for drug discovery as useful models of cancers; however, they do not recapitulate cancers faithfully, especially in the points of rapid growth rate and microenvironment independency. Consequently, the majority of conventional anti-cancer drugs are less sensitive to slow growing cells and do not target microenvironmental support, although most primary cancer cells grow slower than cell lines and depend on microenvironmental support. Here, we developed a novel high throughput drug screening system using patient-derived xenograft (PDX) cells of lymphoma that maintained primary cancer cell phenotype more than cell lines. The library containing 2613 known pharmacologically active substance and off-patent drugs were screened by this system. We could find many compounds showing higher cytotoxicity than conventional anti-tumor drugs. Especially, pyruvinium pamoate showed the highest activity and its strong anti-tumor effect was confirmed also in vivo. We extensively investigated its mechanism of action and found that it inhibited glutathione supply from stromal cells to lymphoma cells, implying the importance of the stromal protection from oxidative stress for lymphoma cell survival and a new therapeutic strategy for lymphoma. Our system introduces a primary cancer cell phenotype into cell-based phenotype screening and sheds new light on anti-cancer drug development.",
author = "Keiki Sugimoto and Fumihiko Hayakawa and Satoko Shimada and Takanobu Morishita and Kazuyuki Shimada and Tomoya Katakai and Akihiro Tomita and Hitoshi Kiyoi and Tomoki Naoe",
year = "2015",
month = "8",
day = "17",
doi = "10.1038/srep13054",
language = "English",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. / Sugimoto, Keiki; Hayakawa, Fumihiko; Shimada, Satoko; Morishita, Takanobu; Shimada, Kazuyuki; Katakai, Tomoya; Tomita, Akihiro; Kiyoi, Hitoshi; Naoe, Tomoki.

In: Scientific Reports, Vol. 5, 13054, 17.08.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells

AU - Sugimoto, Keiki

AU - Hayakawa, Fumihiko

AU - Shimada, Satoko

AU - Morishita, Takanobu

AU - Shimada, Kazuyuki

AU - Katakai, Tomoya

AU - Tomita, Akihiro

AU - Kiyoi, Hitoshi

AU - Naoe, Tomoki

PY - 2015/8/17

Y1 - 2015/8/17

N2 - Cell lines have been used for drug discovery as useful models of cancers; however, they do not recapitulate cancers faithfully, especially in the points of rapid growth rate and microenvironment independency. Consequently, the majority of conventional anti-cancer drugs are less sensitive to slow growing cells and do not target microenvironmental support, although most primary cancer cells grow slower than cell lines and depend on microenvironmental support. Here, we developed a novel high throughput drug screening system using patient-derived xenograft (PDX) cells of lymphoma that maintained primary cancer cell phenotype more than cell lines. The library containing 2613 known pharmacologically active substance and off-patent drugs were screened by this system. We could find many compounds showing higher cytotoxicity than conventional anti-tumor drugs. Especially, pyruvinium pamoate showed the highest activity and its strong anti-tumor effect was confirmed also in vivo. We extensively investigated its mechanism of action and found that it inhibited glutathione supply from stromal cells to lymphoma cells, implying the importance of the stromal protection from oxidative stress for lymphoma cell survival and a new therapeutic strategy for lymphoma. Our system introduces a primary cancer cell phenotype into cell-based phenotype screening and sheds new light on anti-cancer drug development.

AB - Cell lines have been used for drug discovery as useful models of cancers; however, they do not recapitulate cancers faithfully, especially in the points of rapid growth rate and microenvironment independency. Consequently, the majority of conventional anti-cancer drugs are less sensitive to slow growing cells and do not target microenvironmental support, although most primary cancer cells grow slower than cell lines and depend on microenvironmental support. Here, we developed a novel high throughput drug screening system using patient-derived xenograft (PDX) cells of lymphoma that maintained primary cancer cell phenotype more than cell lines. The library containing 2613 known pharmacologically active substance and off-patent drugs were screened by this system. We could find many compounds showing higher cytotoxicity than conventional anti-tumor drugs. Especially, pyruvinium pamoate showed the highest activity and its strong anti-tumor effect was confirmed also in vivo. We extensively investigated its mechanism of action and found that it inhibited glutathione supply from stromal cells to lymphoma cells, implying the importance of the stromal protection from oxidative stress for lymphoma cell survival and a new therapeutic strategy for lymphoma. Our system introduces a primary cancer cell phenotype into cell-based phenotype screening and sheds new light on anti-cancer drug development.

UR - http://www.scopus.com/inward/record.url?scp=84939433151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939433151&partnerID=8YFLogxK

U2 - 10.1038/srep13054

DO - 10.1038/srep13054

M3 - Article

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 13054

ER -